Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomized trial of rapamycin [sirolimus]- and zotarolimus-eluting stents for the reduction of coronary restenosis

Next Previous
Trial Profile

Prospective, randomized trial of rapamycin [sirolimus]- and zotarolimus-eluting stents for the reduction of coronary restenosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Probucol (Primary) ; Sirolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Myocardial ischaemia; Stent thrombosis
  • Focus Therapeutic Use
  • Acronyms ISAR-TEST-5

Most Recent Events

  • 01 Jul 2022 Results (n=4953) of a post-hoc analysis assessing target and non-target vessel related events at 10 years from two clinical studies: NCT00598676 and NCT00598533 published in the Clinical Research in Cardiology
  • 14 Jul 2020 Results published in the Journal of the American College of Cardiology
  • 18 Nov 2019 Results assessing very long term outcomes of patients treated with either permanent polymer-based zotarolimus-eluting stent and polymer-free sirolimus- and probucol-eluting stent were presented at the American Heart Association Scientific Sessions 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top